{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:27:52Z","timestamp":1783031272890,"version":"3.54.6"},"reference-count":18,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hairy cell leukemia (HCL) is a rare disorder characterized by splenomegaly, pancytopenia, and proliferation with \u201chairy\u201d lymphocytes. Treatment is based on purine analogs and anti\u2010CD20 antibodies, often resulting in significant adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The objective of this study is to describe the frequency, clinical, and biological characteristics of a historic cohort of HCL patients in our center and the most common side effects related to treatment with purine analogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p>This study analyzed 21 patients treated between 2009 and 2023, focusing on clinical characteristics, treatment response, complications, and survival outcomes. Cladribine treatment achieved complete response in 77.8% of patients. The 5\u2010year OS and PFS were 100% and 91.7%, respectively. Infections, pathogens such as herpes viruses and mycobacteria, were major complications, impacting 38% of patients. Severe skin reactions were noted in patients treated with cladribine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study highlights cladribine's effectiveness in inducing remission in HCL patients, pointing out the significant risks of infections and other adverse effects. Introducing targeted treatments like BRAF inhibitors provides promising alternatives, especially for resistant patients or those intolerant to purine analogs. Future strategies should focus on integrating targeted therapies to reduce treatment\u2010related morbidity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cnr2.70356","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:44:26Z","timestamp":1759315466000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of Clinical Outcomes and Treatment Complications in Hairy Cell Leukemia: A Single\u2010Center Retrospective Analysis"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3850-957X","authenticated-orcid":false,"given":"M.","family":"Garcia Fasanella","sequence":"first","affiliation":[{"name":"Hematology Department Hospital de la Santa Creu i Sant Pau  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mozos","sequence":"additional","affiliation":[{"name":"Hematology Department Hospital de la Santa Creu i Sant Pau  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Briones","sequence":"additional","affiliation":[{"name":"Hematology Department Hospital de la Santa Creu i Sant Pau  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. F.","family":"Nomdedeu","sequence":"additional","affiliation":[{"name":"Hematology Department Hospital de la Santa Creu i Sant Pau  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Novelli","sequence":"additional","affiliation":[{"name":"Hematology Department Hospital de la Santa Creu i Sant Pau  Barcelona Spain"},{"name":"Hematology Department Institut Catal\u00e0 d\u2019Oncologia Hospital Duran i Reynals. Hospitalet de Llobregat  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014209"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2006.06.008"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005039"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1633640"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010156720"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015851"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010023\u201001962\u20105"},{"issue":"1","key":"e_1_2_11_9_1","first-page":"57","article-title":"The Immunophenotype of Hairy Cell Leukemia (HCL). Proposal for a Scoring System to Distinguish HCL From B\u2010Cell Disorders With Hairy or Villous Lymphocytes","volume":"14","author":"Matutes E.","year":"1994","journal-title":"Leukemia & Lymphoma"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.570820"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv200"},{"key":"e_1_2_11_12_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2022.1068981","article-title":"Novel Targeted Treatments in Hairy Cell Leukemia and Other Hairy Cell\u2010Like Disorders","volume":"12","author":"Maitre E.","year":"2022","journal-title":"Frontiers in Oncology"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010165795"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12735"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-689422"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01419-z"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506583"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300074"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01285-1"}],"updated-by":[{"DOI":"10.1002\/cnr2.70392","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000}}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:01:28Z","timestamp":1761624088000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.70356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/cnr2.70356"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.70356","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"value":"2573-8348","type":"print"},{"value":"2573-8348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2024-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70356"}}